Biosante Pharmaceuticals Jumps 7.50% (STEM, GME, HOS, BPAX, CSX)
StemCells Inc (NASDAQ:STEM) jumped up 9.22% to $2.37. The Company announced interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC product candidate for chronic spinal cord injury continues to demonstrate a favorable safety profile. The data shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines.
GameStop Corp (NYSE:GME) increased 4.82% to $20.0. Goldman Sachs increased the rating on the stock to buy from hold with a 12-month price target of $25.
Hornbeck Offshore Services Inc (NYSE:HOS) declined 1.73% to $38.17 on a traded volume of 89k shares. The Company has expanded its OSV Newbuild Program #5 and has commenced a new 200 Class OSV Retrofit Program. The Company has exercised the first four of its 48 options to build additional HOSMAX vessels at an aggregate incremental cost of approximately $180 million for vessel deliveries in the fourth quarter of 2014 and first quarter of 2015.
Biosante Pharmaceuticals Inc (NASDAQ:BPAX) increased 7.43% to $1.59. The Company announced that the independent Data Monitoring Committee has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder in menopausal women.
CSX Corporation (NYSE:CSX) decreased 2.72% to $21.85 on a traded volume of 2.62 million shares. Dahlman Rose lowered the rating on the stock from buy to hold. The rating was reduced due to expectations for weaker coal shipments.
The executive vice president and chief financial officer, Fredrik Eliasson will address the Seventh Annual UBS Best of Americas Conference in London, on September 6, 2012.